Compare Organon & Co. Common Stock (OGN) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs ON Holding AG — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while ON Holding AG trades at $35.28 (market cap $11.86B). The key difference: ON Holding AG is far larger — about 3.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while ON Holding AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and ON Holding AG for 24 Days on average.
| OGN | ONON | |
|---|---|---|
Market Cap | $3.62B | $11.86B |
Volume | 2,892,999 | 8,624,555 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $50.63 |
52-Week Low | $5.70 | $26.76 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $11.04B | $11.02B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
ONON trades at $35.49, up 0.4% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.44, and announced a $1 billion share buyback program through 2029 alongside ambitious long-term growth targets. Revenue for 2025 was $3.01 billion with a net income margin of 12.3% and robust cash flow from operations of $359.5 million.
The outlook is positive, driven by earnings momentum, strategic expansion, and shareholder returns, but risks include high valuation multiples and competitive pressures. Analyst consensus is strongly bullish with a $42.26 price target, suggesting potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
